Source link : https://www.newshealth.biz/health-news/add-on-to-glp-1s-yields-greater-weight-loss/
TOPLINE: The addition of bupropion/naltrexone to glucagon-like peptide 1 (GLP-1) receptor agonists leads to a further 4%-5% total body weight loss (TBWL) in patients with obesity, including those who show a poor response to initial GLP-1 monotherapy. METHODOLOGY: Some patients with obesity experience suboptimal weight loss with GLP-1 monotherapy; however, adding treatments targeting multiple pathways […]
Author : News Health
Publish date : 2024-05-29 05:35:03
Copyright for syndicated content belongs to the linked Source.
Categories